Oliver Zivanovic

9.1k total citations · 2 hit papers
214 papers, 5.9k citations indexed

About

Oliver Zivanovic is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Surgery. According to data from OpenAlex, Oliver Zivanovic has authored 214 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Reproductive Medicine, 95 papers in Obstetrics and Gynecology and 92 papers in Surgery. Recurrent topics in Oliver Zivanovic's work include Ovarian cancer diagnosis and treatment (124 papers), Endometrial and Cervical Cancer Treatments (86 papers) and Intraperitoneal and Appendiceal Malignancies (61 papers). Oliver Zivanovic is often cited by papers focused on Ovarian cancer diagnosis and treatment (124 papers), Endometrial and Cervical Cancer Treatments (86 papers) and Intraperitoneal and Appendiceal Malignancies (61 papers). Oliver Zivanovic collaborates with scholars based in United States, Germany and Netherlands. Oliver Zivanovic's co-authors include S. Dennis, Nadeem R. Abu‐Rustum, Richard R. Barakat, Mario M. Leitão, Douglas A. Levine, Yukio Sonoda, Ginger J. Gardner, Yukio Sonoda, Carol Aghajanian and Alexia Iasonos and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Oliver Zivanovic

203 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

2009 441 citations S. Dennis, Eric Eisenhauer et al. Gynecologic Oncology profile →
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

2020 224 citations Dmitriy Zamarin, Robert A. Burger et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oliver Zivanovic United States	42	3.3k	2.7k	2.2k	1.5k	809	214	5.9k
Sean Kehoe United Kingdom	35	3.0k 0.9×	2.4k 0.9×	1.9k 0.8×	1.4k 0.9×	579 0.7×	146	5.8k
Amanda N. Fader United States	49	3.0k 0.9×	4.2k 1.6×	2.3k 1.0×	1.6k 1.0×	656 0.8×	222	7.3k
Pamela T. Soliman United States	42	2.6k 0.8×	3.6k 1.4×	1.3k 0.6×	1.7k 1.1×	538 0.7×	220	6.3k
Anna Fagotti Italy	51	5.6k 1.7×	4.7k 1.8×	4.7k 2.1×	1.5k 1.0×	723 0.9×	393	9.0k
Alexander Olawaiye United States	32	2.3k 0.7×	3.0k 1.1×	1.4k 0.6×	911 0.6×	495 0.6×	146	4.8k
John T. Soper United States	51	3.5k 1.1×	3.6k 1.3×	1.5k 0.7×	1.9k 1.3×	826 1.0×	191	8.3k
Ritu Salani United States	36	2.3k 0.7×	1.8k 0.7×	1.3k 0.6×	1.3k 0.9×	419 0.5×	165	4.6k
Michael Frumovitz United States	52	3.8k 1.2×	5.8k 2.2×	2.4k 1.1×	2.3k 1.5×	878 1.1×	262	9.2k
Antonino Ditto Italy	37	2.2k 0.7×	2.4k 0.9×	1.2k 0.5×	803 0.5×	430 0.5×	213	4.4k
Matthew A. Powell United States	35	1.6k 0.5×	2.0k 0.8×	918 0.4×	937 0.6×	549 0.7×	170	3.9k

Countries citing papers authored by Oliver Zivanovic

Since Specialization

Citations

This map shows the geographic impact of Oliver Zivanovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Zivanovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Zivanovic more than expected).

Fields of papers citing papers by Oliver Zivanovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Zivanovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Zivanovic. The network helps show where Oliver Zivanovic may publish in the future.

Co-authorship network of co-authors of Oliver Zivanovic

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Zivanovic. A scholar is included among the top collaborators of Oliver Zivanovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Zivanovic. Oliver Zivanovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Damaty, Ahmed El, Michael Elsässer, Christian Gille, et al.. (2025). The first experience with 16 open microsurgical fetal surgeries for myelomeningocele in Germany. European Journal of Paediatric Neurology. 55. 79–86.

Filippova, Olga T., Vance Broach, Ginger J. Gardner, et al.. (2024). Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecologic Oncology. 187. 80–84. 2 indexed citations

Schram, Alison M., Ramez N. Eskander, Michael W. Sill, et al.. (2024). Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014). Gynecologic Oncology. 190. S56–S57. 1 indexed citations

Park, Kay J., Qin Zhou, Alexia Iasonos, et al.. (2023). Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes (1242). Gynecologic Oncology. 176. S154–S154. 3 indexed citations

Brennan, Donal J., Willemien J. van Driel, & Oliver Zivanovic. (2023). The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer. International Journal of Gynecological Cancer. 33(5). 851–852. 3 indexed citations

Manning‐Geist, Beryl, Renee A. Cowan, Brooke A. Schlappe, et al.. (2022). Assessment of wound perfusion with near-infrared angiography: A prospective feasibility study. Gynecologic Oncology Reports. 40. 100940–100940. 4 indexed citations

Aviki, Emeline, Beryl Manning‐Geist, Tiffanny Newman, et al.. (2021). Risk factors for financial toxicity in patients with gynecologic cancer. American Journal of Obstetrics and Gynecology. 226(6). 817.e1–817.e9. 37 indexed citations

Kaiser, Christina, Alexander Mustea, Andreé Faridi, et al.. (2021). Digital Technical and Informal Resources of Breast Cancer Patients From 2012 to 2020: Questionnaire-Based Longitudinal Trend Study. JMIR Cancer. 7(4). e20964–e20964. 7 indexed citations

Afonso, Anoushka M., Vance Broach, Yukio Sonoda, et al.. (2021). Use of indocyanine green for sentinel lymph node biopsy in patients with iodine or contrast allergy. Gynecologic Oncology. 162. S324–S325.

10.

Zamarin, Dmitriy, Robert A. Burger, Michael W. Sill, et al.. (2020). Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of Clinical Oncology. 38(16). 1814–1823. 224 indexed citations breakdown →

11.

Sisodia, Rachel, Summer Dewdney, Amanda N. Fader, et al.. (2020). Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II. Gynecologic Oncology. 158(1). 201–207. 4 indexed citations

12.

Carter, Jeanne, Helen Huang, Jane M. Armer, et al.. (2020). GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. Gynecologic Oncology. 160(1). 244–251. 45 indexed citations

13.

Rodriguez, Gustavo C., James Kauderer, J. Hunn, et al.. (2019). Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study. Cancer Prevention Research. 12(6). 401–412. 1 indexed citations

14.

Liu, Ying L., Olga T. Filippova, Qin Zhou, et al.. (2019). Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. Journal of Gynecologic Oncology. 31(1). e17–e17. 23 indexed citations

15.

Ko, Emily, Laura J. Havrilesky, Ronald D. Alvarez, et al.. (2018). Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). Gynecologic Oncology. 149(2). 232–240. 9 indexed citations

16.

Piedmonte, Marion, Paul K. J. Han, Richard P. Moser, et al.. (2017). Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study. Obstetrical & Gynecological Survey. 72(6). 336–337. 1 indexed citations

17.

Roche, Kara Long, et al.. (2017). Risk‐reducing salpingectomy: Let us be opportunistic. Cancer. 123(10). 1714–1720. 26 indexed citations

18.

Tseng, Jill, R.S. Suidan, Oliver Zivanovic, et al.. (2016). Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. Gynecologic Oncology. 142(2). 217–224. 41 indexed citations

19.

Sandadi, Samith, K. Long, Vaagn Andikyan, et al.. (2013). Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. Gynecologic Oncology. 132(2). 299–302. 13 indexed citations

20.

Dennis, S., Oliver Zivanovic, Eric Eisenhauer, et al.. (2008). A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecologic Oncology. 112(1). 6–10. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact